Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | PDE2A | O00408 | 8/20 | 0.41 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | KDM1A | O60341 | 1/20 | 0.36 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.36 |
| ▸ | IL1B | P01584 | 1/20 | 0.36 |
| ▸ | EIF4E | P06730 | 1/20 | 0.35 |
| ▸ | SCD | O00767 | 1/20 | 0.35 |
| ▸ | AR | P10275 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3204474 | 0.83 | KCNH2 (0.42) | HSD11B1CYP1A2 | |
| SCHEMBL2615355 | 0.83 | MPL (0.50) | HSD11B1CYP1A2PDE2AGRM2 | |
| SCHEMBL2609369 | 0.81 | PDE2A (0.44) | HSD11B1CYP1A2PDE2AGRM2NPSR1 | |
| SCHEMBL17826999 | 0.81 | CTSS (0.40) | HSD11B1CYP1A2PDE2AGRM2NPSR1 | |
| SCHEMBL25400896 | 0.79 | TP53 (0.48) | CYP1A2PDE2APDE10A | |
| SCHEMBL31399815 | 0.79 | TP53 (0.48) | CYP1A2PDE2APDE10A | |
| SCHEMBL13265493 | 0.79 | CYP1A2 (0.39) | HSD11B1CYP1A2IL1B | |
| SCHEMBL19785361 | 0.75 | PDE2A (0.52) | HSD11B1PDE2AGRM2NPSR1EIF4E | |
| SCHEMBL2615845 | 0.73 | KIF11 (0.45) | CYP1A2KDM1A | |
| SCHEMBL2615360 | 0.71 | KDM4E (0.56) | CYP1A2KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8785445-B2 | 7-phenoxychroman carboxylic acid derivatives | ARRAY BIOPHARMA INC. (US) | 2014-07-22 | — | — | US | disclosed |
| US-20120101103-A1 | 7-PHENOXYCHROMAN CARBOXYLIC ACID DERIVATIVES | ARRAY BIOPHARMA INC. (US) | 2012-04-26 | — | — | US | disclosed |
| WO-2010075200-A1 | 7-PHENOXYCHROMAN CARBOXYLIC ACID DERIVATIVES | ARRAY BIOPHARMA INC. (US) | 2010-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101103-A1 | 7-PHENOXYCHROMAN CARBOXYLIC ACID DERIVATIVES | PTGDR2, PTGDR, HRH2 | HSD11B1 541/4885CYP1A2 155/4885PDE2A 317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.